Synonym
Cyclodisone; NSC348948; NSC348948; NSC-348948
IUPAC/Chemical Name
1,5,2,4-Dioxadithiepane, 2,2,4,4-tetraoxide
InChi Key
RYIRMSRYCSMGJA-UHFFFAOYSA-N
InChi Code
InChI=1S/C3H6O6S2/c4-10(5)3-11(6,7)9-2-1-8-10/h1-3H2
SMILES Code
O=S(OCCOS1(=O)=O)(C1)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
202.19
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Berardini MD, Pacheco DY, Gibson NW. Structure activity analysis of the formation of DNA damage induced in human tumor cells by the cyclodisone class of anti-tumor agent. Anticancer Drug Des. 1991 May;6(2):119-27. PMID: 2039582.
2: Gibson NW. Comparison of the in vitro cytotoxicity of cyclodisone with a series of structurally related analogues. Anticancer Drug Des. 1988 Dec;3(3):199-204. PMID: 3272138.
3: Gibson NW. Characterization of DNA damage and cytotoxicity induced in two human colon carcinoma cell lines by cyclodisone. Cancer Res. 1989 Jan 1;49(1):154-7. PMID: 2908842.
4: Dive C, Workman P, Watson JV. Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry. Cancer Chemother Pharmacol. 1989;25(3):149-55. doi: 10.1007/BF00689574. PMID: 2557170.
5: Umprayn K, Kennedy PE, Lee JC, Waugh W, Riley CM, Stella VJ. Development of reversed-phase HPLC assays for cyclodisone and clomesone. J Pharm Biomed Anal. 1987;5(6):625-33. doi: 10.1016/0731-7085(87)80075-4. PMID: 16867487.
6: Gibson NW, Hartley JA, Kohn KW. DNA reactivity and in vitro cytotoxicity of the novel antitumor agent 1,5,2,4-dioxadithiepane-2,2,4,4-tetraoxide (NSC-348948) in human embryo cells. Cancer Res. 1986 Apr;46(4 Pt 1):1679-83. PMID: 3509975.
